Loading…
Live feed of every catalyst classified under Regulatory and Clinical.
Company highlights overall response rates in patients with relapsed lymphoma.
Company leverages proprietary TRBC platform technology for enhanced immune activation.
The study is evaluating a novel brain hormone therapy targeting the stress response.
Results from a recent pharmacokinetic simulation analysis were announced.
The approval follows the device's successful clearance in the European Union.
Soligenix received a significant regulatory designation for its therapeutic candidate.
Regulatory clearance expands market reach for preeclampsia risk assessment.
